Abstract

**Background:** Unintentional medication nonadherence is common and has been associated with poor health outcomes and increased health care costs. Earlier research demonstrated a relationship between habit strength and medication adherence. Previous research also examined a habit’s direct effect on adherence and how habit interacts with more conscious factors to influence or overrule them. However, the relationship between habit and adherence and the role of habit-based mobile health (mHealth) interventions remain unclear.

**Objective:** This review aimed to systematically evaluate the most recent evidence for habit strength, medication adherence, and habit-based mHealth interventions across chronic medical conditions.

**Methods:** A keyword search with combinations of the terms *habit, habit strength, habit index, medication adherence,* and *medication compliance* was conducted on the PubMed database. After duplicates were removed, two authors conducted independent abstract and full-text screening. The guidelines for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were followed when reporting evidence across the included and reviewed studies.

**Results:** Of the 687 records examined, 11 met the predefined inclusion criteria and were finalized for data extraction, grading, and synthesis. Most included studies (6/11, 55%) were cross-sectional and used a theoretical model (8/11, 73%). The majority of studies measured habit strength using the self-report habit index and self-report behavioral automaticity index (9/11, 82%). Habit strength was positively correlated with medication adherence in most studies (10/11, 91%). Habit mediated the effects of self-efficacy on medication adherence (1/11, 9%), and social norms moderated the effects of habit strength on medication adherence (1/11, 9%). Habit strength also moderated the effects of poor mental health symptoms and medication adherence (1/11, 9%). None of the included studies reported on using or proposing a habit-based mHealth behavioral intervention to promote medication adherence.

**Conclusions:** Habit strength was strongly correlated with medication adherence, and stronger habit was associated with higher medication adherence rates, regardless of the theoretical model and/or guiding framework. Habit-based interventions should be used to increase medication adherence, and these interventions could leverage widely available mobile technology tools such as mobile apps or text messaging, and existing routines.
Introduction

Background

Medication adherence is defined as taking medication exactly as prescribed [1]; this includes taking the proper dose at the right time. Medication adherence comprises three components: initiation, implementation, and persistence [2]. Medication nonadherence can occur at any of these three stages because of the failure to initiate a new prescription, implement it as prescribed, or persist with treatment [2]. Medication adherence is not a dichotomous variable (ie, adherence vs nonadherence) [2] but is more of a continuum (ie, variable levels of adherence). Lower adherence and variations in adherence can lead to loss of drug effectiveness, toxicity, and drug resistance [3]. Only approximately 50% of medications are taken as recommended in different patient populations [4-6], including children with chronic conditions [7,8]. The costs of low medication adherence are both personal and economic. In the United States, this has been shown as a cycle where poor medication adherence leads to poor patient outcomes [9-15] and increased service utilization and health care costs [9,10,12,16], all of which are passed down to the patient, further affecting adherence [17]. The Institute for Healthcare Informatics identified US $500 billion in savings across 186 countries with the responsible use of medication and noted that about 8% of the global total health expenditure could be avoided by improving adherence to medication [2].

Habit is the context-dependent automatic completion of a behavior [18]. Medication adherence would be an example of such a behavior where patients may take the same number of pills in the same room at the same time of day. Therefore, high habit strength is the result of recurring contextual cues [19]. As habit is automatic, it works independently of, and can even override, conscious desires when strong enough [19]. There are 2 types of medication nonadherence: intentional and unintentional [20]. Forgetfulness is the number one cause of unintentional nonadherence [21]. As habit is independent of conscious cognitive processes, having high habit strength protects against forgetfulness. Earlier research demonstrated a relationship between the strength of habit and medication adherence. Previous research examined habit’s direct effect on adherence and how habit interacts with more conscious factors to influence or overrule them [22]. However, the relationship between habit and adherence remains unclear.

Access to personal and mobile technology is ubiquitous [23-25], and there has been strong evidence to support the efficacy of digital or mobile health (mHealth) behavioral interventions, in particular text messaging and apps as tools to improve medication adherence [26-34]. These findings make mHealth interventions an appealing approach to optimize habit formation and medication adherence behavior in pediatric and adult patients with chronic health conditions [35]. However, the cost-effectiveness of these interventions remains unclear [36,37].
(GRADE) criteria were used [39]. The GRADE approach evaluates a body of evidence by starting with a quality level based on the underlying methodology and then upgrading or downgrading the quality level based on various factors. Randomized trials or double-upgraded observational studies were rated as high. Downgraded randomized trials or upgraded observational studies were rated as moderate. Double-downgraded randomized trials or observational studies were rated as low. Triple-downgraded randomized trials and observational studies were rated very low. Factors that downgrade the quality of evidence include limitations that suggest bias, indirectness of evidence, unexplained heterogeneity or inconsistency of results, imprecision of results, or a high probability of publication bias.

Factors that improve the quality of evidence include a large magnitude of effect (ie, when all plausible confounding factors reduce a demonstrated effect or suggest a spurious effect when results show no effect) and dose-response gradient [38]. Data were analyzed and summarized qualitatively.

Results

Literature Search

Our literature search identified 687 studies for screening (title and abstract). Of these, 41 full-text studies were reviewed, and 11 studies [9-12,20,22,40-44] met all inclusion criteria. This process is outlined in the PRISMA flow chart (Figure 1).

Figure 1. Flow of studies through the review according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Description of Included Studies

Study Characteristics

Table 1 summarizes the study characteristics. The research from the included studies was conducted across a range of countries, including 1 study from the Netherlands [22], 2 from Canada [10,20], 2 from Ireland [40,41], 3 from the United Kingdom [11,43], and 3 from the United States [9,42,44]. All the included studies were published over the past 9 years, with the oldest published in 2011 [22] and the most recent in 2019 [11]. All studies included studies on habit strength and medication adherence in a specific chronic disease population including asthma [22], type 2 diabetes [10,20,42], hypertension [9,40,44], cystic fibrosis [11,12], and psoriasis [43], except for 1 study that looked at a population taking oral contraceptives [41]. All studies included adult subjects, but the participants’ mean age ranged greatly from 22.41 to 69.86 years. The number of participants varied as well; the included studies ranged from 61 to 901 participants, with a mean of 331.82 participants and a median of 202 participants. The majority of the studies had a roughly equal ratio of male to female participants. One study observed a veteran population [44] with a mean age of 64.1 years, and only 14% women were included in the study [44]. Owing to the nature of the population, a study on oral contraceptives had a 100% female population [41]. Most studies (n=6) were cross-sectional [10,20,22,40,43], 4 were longitudinal studies [9,12,42,44], and 1 was a pilot randomized control trial [11]. In the included studies, medication adherence was measured using a combination of self-report questionnaires, remote monitoring using electronic pill bottles, and in-person interviews. The majority of studies (9/11, 82%) measured habit strength using the self-report habit index and self-report behavioral automaticity index [9-11,20,22,40-43].
### Table 1. Summary of included studies that evaluated habit strength and medication adherence.

| Source (country) | Health condition | Participants (N) | Age (years), mean (SD) | Sex (female), n (%) | Study design | Theoretical model | Quality of evidence |
|------------------|------------------|------------------|------------------------|---------------------|-------------|-------------------|---------------------|
| Bolman et al [16] (Netherlands) | Asthma | 139 | 31.5 (5.60) | 99 (71) | Cross-sectional study | ASEb model | Mail-out survey, questionnaire | Low |
| Burns et al [14] (Canada) | Type 2 diabetes | 790 | 64.05 (8.20) | 387 (49) | Cross-sectional study | CS-SRMc | Telephone interview, questionnaire | Moderate |
| Durand et al [19] (Ireland) | Hypertension | 204 | 69.86 (10.69) | 86 (42) | Cross-sectional study | TPBD | Questionnaire | Low |
| Guenette et al [8] (Canada) | Type 2 diabetes | 901 | 62.70 (9.10) | 369 (41) | Cross-sectional study | CS-SRM | Questionnaire | Very low |
| Hoo et al [10] (United Kingdom) | Cystic fibrosis | 123 | 25.00 (19-31) | 52 (42) | Longitudinal study | Habit index measure | Electronic pill bottle | Very low |
| Hoo et al [9] (United Kingdom) | Cystic fibrosis | 61 | 27.40 (21.70-37.10) | 28 (46) | Pilot randomized control trial | COM-Bg model | Questionnaire, electronic pill bottle | Very low |
| Murphy et al [20] (Ireland) | Oral contraceptive pill | 245 | 22.41 (4.78) | 245 (100) | Cross-sectional study | — | Questionnaire | Very low |
| Phillips et al [7] (United States) | Hypertension | 71 | 67.9 (12.28) | 45 (63) | Longitudinal study | CS-SRM | Interview, MEMSb | Low |
| Phillips et al [21] (United States) | Type 2 diabetes | 103 | 56.96 (12.94) | 64 (62) | Longitudinal study | CS-SRM | Interview, electronic pill bottle, Fitbit, survey | Very low |
| Thornloe et al [22] (United Kingdom) | Psoriasis | 811 | 48.10 (13.10) | 349 (43) | Cross-sectional cohort study | CS-SRM | Questionnaire | Moderate |
| Voils et al [23] (United States) | Hypertension | 202 | 64.10 (11.00) | 28 (14) | Longitudinal study | — | Survey | Very low |

aQuality of evidence assessed using the Grades of Recommendation, Assessment, Development, and Evaluation criteria.

bASE: attitude, social influence, and self-efficacy model.

cMissing data were not reported in the included studies.

dCS-SRM: common sense model of self-regulation.

eTPB: theory of planned behavior.

fMedian age (years) is reported when the mean age was not provided in the included studies. IQR in parenthesis.

gCOM-B: capability, opportunity, motivation, and behavior.

hMEMS: medication event monitoring system.

### Description of Guiding Models

Different behavioral models exist to explain the process that occurs before a behavior takes place. In the context of this systematic review, the behavior being studied is medication adherence. Most studies (8/11, 73%) included theoretical models that comprised the guiding framework [9-12,22,40,42,43]. A variety of theoretical models were used by the included studies: the attitude, social influence, and self-efficacy model (ASE) [22]; the common sense model of self-regulation (CS-SRM) [9,40,42,43]; the theory of planned behavior (TPB) [10]; and the capability, opportunity, motivation, and behavior model (COM-B) [11].

The ASE is a behavioral explanatory model that takes a look at attitude, social influence, and self-efficacy as the predictors of intention and behavioral change [22]. Adapting the model to medication adherence, attitude is referred to as “the perceived pros and cons of taking medication,” social influence included “perceived norms and support of important others toward medication adherence and modeling which is the perceived behavior of others,” and self-efficacy was defined as “the...
person’s belief that they could adhere to medicine” [22]. Habit was observed as either a moderating or mediating factor in this model.

The CS-SRM proposes that an individual has a certain representation of an illness in their mind that guides how they respond to an illness threat [45]. The components of the illness representation are identity, causes, consequences, timeline, and controllability [40]. In the context of this systematic review, the response to illness threat would be medication adherence. According to the CS-SRM model, treatment-favorable beliefs lead to the initiation of behavior, and experiential feedback proves that those beliefs were correct (CS-SRM coherence), and the behavior was practiced until it became habit, leading to long-term medication adherence [9].

Fundamentally, the TPB states that attitudes, subjective norms, and perceived behavioral control create the intention to perform behaviors such as medication adherence [10]. When an individual is given sufficient control over their situation, intention will be turned into behavior when given the opportunity to do so [10]. The included study that used the TPB as a guiding model [10] examined habit as another factor that influences intention and the performance of medication adherence behavior.

The COM-B is a behavior system in which capability, opportunity, and motivation interact and lead to behavior [46]. The behavior itself, then, influences capability, opportunity, and motivation. Capability includes knowledge, cognitive ability, and physical skills to perform a behavior. Opportunity is defined as factors that lie outside the patient’s environment that make taking medications possible or prompt them to do so according to the cultural milieu, including the access to medications and medical care as well as the perceptions related to disease stigma. In other words, opportunity includes any factor that is not in the hands of the individual. Motivation energizes and directs behavior. Goals, conscious decision-making, habitual processes, emotional responding, and analytical decision-making are all components of motivation. In the context of this systematic review, habit is part of the automatic motivation that energizes and directs the behavior of medication adherence.

Description of Habitat Strength Measures
Table 2 summarizes the habit strength and adherence measure as well as the main outcomes. The majority of studies (9/11, 82%) measured habit strength using the self-report habit index and self-report behavioral automaticity index [9-11,20,22,40-43]. The self-report behavioral automaticity index is a subset of the self-report habit index, and an example item from this index would be taking this medication is something I do automatically, which is rated on a scale of 1-5 from strongly disagree=1 to strongly agree=5 [21]. One study [9] modified this scale by adding 4 additional questions that evaluated the concept of habit strength more broadly and intuitively (ie, asking patients in different ways whether or not they have a habit of taking their medication vs asking them in different ways if they take their medication without conscious attention, without conscious awareness, etc). One of the studies [12] built and tested a new form of measuring habit strength, using the habit index scale as its guiding model. A total of 2 studies [12,44] used the multiplicative product of behavior frequency and context stability.
### Table 2. Summary of habit strength, medication adherence measures, and outcomes in the included studies.

| Source                  | Habit strength measure                           | Adherence scale and rates                                      | Relationship between habit strength and adherence rates |
|-------------------------|-------------------------------------------------|-----------------------------------------------------------------|--------------------------------------------------------|
| Bolman et al [16]       | • SRHI<sup>a</sup>                               | • MARS<sup>b</sup>                                              | • Correlation \( r = 0.61; \) \( P < .001 \)           |
| Burns et al [14]        | • Self-report behavioral automaticity index      | • Did you ever forget to take your medication? on a 5-point scale | • Depressive symptoms: beta = 0.08; \( P < .001 \); 95% CI 0.04 to 0.12 |
|                         |                                                  | • MARS                                                           | • Diabetes distress: beta = 0.09; \( P < .001 \); 95% CI 0.04 to 0.12 |
|                         |                                                  | • SRHI                                                           | • Major depressive syndrome: beta = 0.07; \( P < .001 \); 95% CI 0.03 to 0.11 |
| Durand et al [19]       | • Self-report behavioral automaticity index      | • Overall adherent range: 58.9%-79.7%                           | • MARS: correlation \( r = 0.36; \) \( P < .001 \)       |
|                         |                                                  | • MARS: 36.7% nonadherent                                        | • MMAS: correlation \( r = 0.35; \) \( P < .001 \)       |
|                         |                                                  | • MMAS<sup>c</sup>: 41.1% nonadherent                            | • Prescription refill: correlation \( r = 0.08 \)         |
|                         |                                                  | • Prescription refill: 79.7% adherent                            | • urine assay: correlation \( r = -0.02 \)                |
|                         |                                                  | • Urine assay                                                    | • Adherence composite: correlation \( r = 0.36; \) \( P < .001 \) |
|                         |                                                  | • Total nonadherence, 2.1%                                       | • Hierarchical regression analysis: beta = 0.44; \( P < .001 \); adjusted. \( R^2 = 0.22, \Delta R^2 = 0.19; \) \( P < .001 \) |
|                         |                                                  | • Partial nonadherence, 23.8%                                    | • Unintentional adherence: beta = -0.45; \( t_{203} = -7.04; \) \( P < .001 \) |
|                         |                                                  | • Adherence consistently low: \( R = 0.40; \) \( 95\% \) CI 0.36 to 0.44; beta = 0.30; 95% CI −1.04 to 1.65 |
|                         |                                                  | • Adherence consistently low: \( R = 0.24; \) \( 95\% \) CI 0.04 to 0.44; beta = 3.03; 95% CI −9.68 to 15.76 |
|                         |                                                  | • Variable adherence: \( R = 0.45; \) \( 95\% \) CI 0.41 to 0.49; beta = 0.08; 95% CI −1.44 to 1.60 |
|                         |                                                  | • Adherence consistently high: \( R = 0.20; \) \( 95\% \) CI 0.13 to 0.27; beta = 0.61; 95% CI −1.90 to 3.13 |
| Guenette et al [8]      | • SRHI                                           | • MMAS-8 modified French version                                 | • Adjusted OR<sup>d</sup> 1.65; 95% CI 1.35 to 2.03; \( P < .001 \) |
|                         | • About 71% scoring high (at least 5/6)          | • 45% high adherence                                            |                                                        |
|                         | • Mea                                             | • 40.7% medium adherence                                         |                                                        |
|                         |                                                  | • 14.3% low adherence                                            |                                                        |
| Hoo<sup>b</sup> et al [10] | • Multiplicative product of behavior frequency and context stability | • Electronic pill bottles                                        | • Overall cohort: \( R = 0.40; \) \( 95\% \) CI 0.36 to 0.44; beta = 0.30; 95% CI −1.04 to 1.65 |
|                         |                                                  | • 47.30% median adherence                                        | • Adherence consistently low: \( R = 0.24; \) \( 95\% \) CI 0.04 to 0.44; beta = 3.03; 95% CI −9.68 to 15.76 |
|                         |                                                  | • 4.9% low adherence                                             | • Variable adherence: \( R = 0.45; \) \( 95\% \) CI 0.41 to 0.49; beta = 0.08; 95% CI −1.44 to 1.60 |
|                         |                                                  | • 80.5% variable adherence                                       | • Adherence consistently high: \( R = 0.20; \) \( 95\% \) CI 0.13 to 0.27; beta = 0.61; 95% CI −1.90 to 3.13 |
|                         |                                                  | • 14.6% high adherence                                           | • All significantly correlated with adherence levels, \( P < .001 \) |
| Hoo<sup>b</sup> et al [9] | • Self-report behavioral automaticity index       | • Chipped nebulizer                                              | • Median habit strength in different subgroups:          |
|                         |                                                  | • 75.4% low adherence                                            | • Low adherence: 9.0, IQR 4.8-12.0                        |
|                         |                                                  | • 13.1% medium adherence                                         | • Moderate adherence: 14.5, IQR 11.3-18.3                 |
|                         |                                                  | • 11.5% high adherence                                           | • High adherence: 18.0, IQR 14.0-20.0                     |
|                         |                                                  | • Adherence consistently high: \( R = 0.20; \) \( 95\% \) CI 0.13 to 0.27; beta = 0.61; 95% CI −1.90 to 3.13 |
|                         |                                                  | • All significantly correlated with adherence levels, \( P < .001 \) |
| Murphy et al [20]       | • Self-report behavioral automaticity index       | • MARS                                                           | • Correlation \( r = -0.24^2; \) \( P < .001 \)          |
|                         | • Mean habit strength per number OCP<sup>f</sup> missed per month | • Mean MARS score per number of OCP missed per month:           |                                                        |
|                         |                                                  | • Never: 5.85                                                   |                                                        |
|                         |                                                  | • Once: 7.49                                                   |                                                        |
|                         |                                                  | • Twice or more: 10.12                                          |                                                        |
### Relationship between habit strength and adherence rates

**Adherence scale and rates**
- MARS, MMAS, MEMS
- Mean adherence
- MMAS: 0.80
- MEMS timing adherence: 76%
- MEMS dosing adherence: 96%

**Habit strength measure**
- Self-report habit index, with 4 additional questions
- Self-report behavioral automaticity index
- Mean medication-taking habit strength 3.75
- Self-report habit index
- Mean 41.5 for self-administered systemic therapy
- Product of frequency and mean of 5 situational consistency items

**Relationship between habit strength and adherence rates**
- Bivariate relationship (correlations):
  - MARS: 0.37
  - MMAS: 0.26
  - MEMS dose frequency: 0.42
  - MEMS dose timing: 0.49
- Hierarchical regression analysis:
  - MARS: $\Delta R^2 = 0.11; P < .01$
  - MMAS: $\Delta R^2 = 0.06; P = .04$
  - MEMS frequency: $\Delta R^2 = 0.17; P < .001$
  - MEMS timing: $\Delta R^2 = 0.27; P < .001$
- Unintentional nonadherence: $\beta = -.32; t_{66} = -2.55; P = .01$
- Intentional nonadherence: $\beta = -.23; t_{66} = -1.82; P < .07$

#### Phillips et al [7]

- Self-report habit index, with 4 additional questions
- Self-report behavioral automaticity index
- Mean medication-taking habit strength 3.75

#### Phillips et al [21]

- Self-report habit index
- Mean 41.5 for self-administered systemic therapy

#### Thorneloe et al [22]

- Self-report habit index
- Mean 41.5 for self-administered systemic therapy

#### Voils et al [23]

- Product of frequency and mean of 5 situational consistency items

---

aSRHI: self-report habit index.
bMARS: medication adherence report scale.
cMMAS: Morisky medication adherence scale.
dZ-scores averaged. So greater MARS and MMAS scores represented greater nonadherence.
eOR: odds ratio.
fOCP: oral contraceptive pill.
gNegative because lower MARS score represents better adherence.
hMEMS: medication event monitoring system.
Description of Adherence Measures

The most common measures of adherence were the medication adherence report scale [9,22,40-43] and the Morisky medication adherence scale [9,10,40,44]. Other measures of adherence included medication event monitoring systems [7,9,21], medication possession ratio based on prescription refill data [19], single item self-report [14], and urine drug monitoring [14].

Study Methodological Quality

The quality of the included studies ranged from very low to moderate. Of the 11 included studies, 2 were of moderate quality [20,43], 3 were of low quality [9,22,40], and 6 were of very low quality [10-12,41,44]. Table 1 reports the quality of each included study.

Description of Study Outcomes

Habit Strength, Medication Adherence, and Mobile Health Interventions

Table 3 summarizes the study outcomes related to habit strength and medication adherence. Most studies showed a positive correlation between habit strength and medication adherence behavior, suggesting stronger habit formation with higher medication adherence rates [9-12,22,40-44]. Furthermore, compared with factors such as pill burden [40], illness coherence [40], treatment-related beliefs [9,40], and experiences with treatment-related efficacy [9], habit strength was the strongest predictor of adherence. Habit strength had the strongest association with medication adherence and medication event monitoring system dose timing among all the other adherence measures in 1 study [9]. However, habit strength was found to be equally correlated to dose timing and days taken in a later study [42].

Habit strength was also found to mediate the effects of self-efficacy on adherence [22]. The effect of self-efficacy on adherence disappeared once habit strength was added to the hierarchical multiple regression analysis model, and this relationship was confirmed with bootstrapping analysis [22]. Social norms moderated the relationship between habit strength and medication adherence; in weak habit, a supportive norm of taking medicine was positively related to adherence, and supportive norms were only positively correlated with adherence when habit strength score was low [22].

Even after adjusting for covariates, such as age and disease duration, habit strength moderated the association between poor mental health symptoms and medication adherence [20]. Interaction between habit strength and depressive symptoms was also observed. When habit strength was weak or average, depressive symptoms were negatively associated with adherence [20]. However, if habit was strong, no association was observed [20]. This same interaction was observed between diabetes distress and habit strength as well as between major depressive syndrome and habit strength [20].

Habit strength was more strongly associated with unintentional nonadherence than intentional nonadherence in 2 studies [9,40] but was equally predictive in another study [42]. None of the included studies reported on using or proposing a habit-based mHealth behavioral intervention to promote medication adherence.
Table 3. Summary of the main study findings.

| Source            | Study outcomes                                                                                                                                                                                                                                                                                                                                 |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Bolman et al [16] | • Higher habit strength is positively correlated with higher adherence.  
• Habit mediates the relationship between self-efficacy and medication adherence.  
• Social norms moderate the relationship between habit and adherence; in weak habit, a supportive norm of taking medicine was positively related to adherence, and in strong habit, supportive norm correlated with less adherence.  
• Perceiving few negative consequences of taking medicine was associated with better adherence.  
• Control variables of risk perception and asthma severity were positively correlated with adherence.  
• Female gender was positively correlated with adherence.  
• Control variable of internal locus of control negatively correlated with adherence.  
• From the central concepts, perceiving more pros, social support, higher self-efficacy, and stronger habit was associated with more adherence.  
• From the central concepts, habit strength and attitude pros had the strongest correlation with medication adherence.  
• Social norm and modeling were not significantly associated with adherence.  
• Social influence subscales were highly intercorrelated, as well as habit with risk perception, pros, social support, and self-efficacy.  
• After hierarchical multiple regression, habit strength proved to be significantly related to adherence. Of the control variables, only severity remained significant; of the ASE² concepts, only the cons remained significant. |
| Burns et al [14]  | • Interaction between habit strength and depressive symptoms was observed. If habit strength was weak or average, depressive symptoms were negatively associated with adherence. However, if habit was strong, no association was observed.  
• Same significant interaction pattern was observed for diabetes distress and habit strength as well as major depressive syndrome and habit strength.  
• Habit strength moderates the association between poor mental health symptoms and medication adherence.  
• After adjusting for covariates, results remained significant. |
| Durand et al [19] | • Medication-taking habit strength was the strongest predictor of adherence (compared with pill burden, illness coherence, and treatment-related beliefs).  
• Habit strength explained 19% incremental variance in adherence beyond treatment-related beliefs.  
• Habit strength was more strongly associated with unintentional nonadherence than intentional.  
• Associations among adherence measures were weak to moderate, indicating that multiple measures are necessary to accurately assess adherence.  
• Neither treatment-related beliefs nor CSM² coherence predicted adherence, even for patients with weak habit strength.  
• Pill burden was not associated with habit strength or adherence.  
• There was no significant interaction between treatment-related beliefs, habit strength, and adherence. |
| Guenette et al [8] | • Strong habit was significantly associated with adherence.  
• Perceived behavioral control, older age, no perceived side effects, a longer period since T2D diagnosis, and a lower number of NAIAD daily doses were significantly associated with adherence.  
• Sex, level of education, and income are not associated with adherence.  
• Intention, insulin use, number and type of NAIAD drugs prescribed, perceived cost of antidiabetes medications, and use of glucometer or weekly pill organizer were not associated with NIAD adherence.  
• Depressed mood, anxiety, and mental health were not associated with adherence.  
• Behavioral control was found to be significant, so the 26 underlying beliefs were analyzed, and 12 beliefs were found to be significant with adherence. |
| Hooö et al [10]   | • One unit increase in habit index was associated with a 0.3% increase in the subsequent week’s adherence after controlling for current adherence.  
• Those with variable adherence displayed higher mean cross-correlation coefficients (0.45) compared with those with consistent adherence (0.20-0.40). |
| Hooö et al [9]    | • Higher adherers reported stronger habit compared with lower adherers.  
• A 1-unit increase in habit strength was associated with a 31% increase in odds of being in the next higher adherence category.  
• In a multiple ordinal regression model with both habit and concerns scores, only habit was associated with adherence.  
• Higher adherers had lower prior year intravenous use, tended to have higher %FEV⁶ at baseline, and reported lower concerns. |
| Murphy et al [20] | • Stronger habit strength was associated with better adherence.  
• Those who never miss an OCP² reported significantly higher habit strength than those who miss 2 or more per month.  
• There was no difference between those who never miss an OCP and those who miss 1 OCP per month.  
• Having a fixed time of day to take the OCP was associated with better habit strength and adherence.  
• There is, however, no association between habit strength and taking OCP at different times of the day.  
• Having a fixed place to store the OCP was associated with habit strength but not adherence. |

http://www.jmir.org/2020/4/e17883/
concluded that longer treatment duration led to higher adherence associated with adherence in 2 different studies. One study [10,43]. Longer treatment duration was found to be significantly associated with perceived behavioral control [10], and older age perceived negative consequences of taking the medication associated with increased medication adherence included habit strength, other factors significantly associated with adherence in 2 different studies. One study [10,11,22,43], habit strength was more strongly related to unintentional medication nonadherence than intentional nonadherence. Patients’ CS-SRM coherence was more strongly associated with intentional nonadherence than unintentional adherence. Patients’ treatment-related beliefs were not more strongly associated with intentional nonadherence than unintentional nonadherence.

Habit strength had the strongest association with MEMS dose timing out of all the adherence measures. The interaction between treatment-related beliefs and habit was not significant for any of the adherence measures. Patients’ beliefs and experiences did not predict overall adherence, even for weaker adherence. Patient experience, however, did predict intentional nonadherence.

Patients in the biological cohort were more likely to be male, have a younger age of onset of psoriasis, longer duration of disease, more likely to have a diagnosis of inflammatory arthritis, have lower quality of life scores at the start of therapy, have longer duration of systemic therapy, have stronger beliefs in the chronicity of their illness, stronger beliefs that systemic therapy is necessary, weaker concerns about therapy and medicine, greater coherence, and less symptoms of depression.

Patients using self-administered systemic therapy had strong habit strength. Being on a conventional systemic therapy, having strong medication concerns, longer treatment duration, and younger age were factors associated with overall nonadherence. Being on a conventional therapy and strong medication concerns were also significant for intentional nonadherence. Being on a conventional systemic therapy, stronger perceptions of psoriasis being a chronic condition, younger age, and longer treatment duration were factors associated with unintentional nonadherence.

Group 1 membership (strongest medication concerns) was associated with intentional nonadherence, and weaker medication-taking routine or habit strength was associated with unintentional nonadherence.

Dual conceptualization (self-report with psychometric principles) of medication nonadherence has stronger validity and reliability than other forms that confound these 2 variables. Extent of adherence was highly correlated with self-efficacy, where lower adherence levels were associated with lower self-efficacy.

In all, 3 items assessing the extent of nonadherence produced reliable scores. Correlations and comparison measures showed convergent and divergent validity. Predictive validity was evidenced by correlations between extent and BP. Means of the reasons items were well below the scale midpoint, and several distributions were positively skewed and kurtosis. The Morisky scale did not measure a single underlying construct in this sample. The Morisky scale was not correlated with BP.

Habit strength was the strongest predictor of medication adherence (compared with beliefs and experiences plus efficacy)—explains 6%-27% incremental variance in adherence to that explained by treatment-related beliefs. Habit strength was more strongly related to unintentional medication nonadherence than intentional nonadherence. Patients’ CS-SRM coherence was more strongly associated with intentional nonadherence than unintentional adherence. Patients’ treatment-related beliefs were not more strongly associated with intentional nonadherence than unintentional nonadherence.

Habit strength had the strongest association with MEMS dose timing out of all the adherence measures. The interaction between treatment-related beliefs and habit was not significant for any of the adherence measures. Patients’ beliefs and experiences did not predict overall adherence, even for weaker adherence. Patient experience, however, did predict intentional nonadherence.

Habit strength consistently predicted incremental variance in measured outcomes, both self-reported and measured. Correlations, between habit strength and % of the doses taken on time vs between habit strength and % of the days when medications were taken, were not significantly different.

Habit strength does not predict unintentional nonadherence better than intentional. Habit strength is not relatively more important for predicting medication adherence than physical activity.

Patients in the biological cohort were more likely to be male, have a younger age of onset of psoriasis, longer duration of disease, more likely to have a diagnosis of inflammatory arthritis, have lower quality of life scores at the start of therapy, have longer duration of systemic therapy, have stronger beliefs in the chronicity of their illness, stronger beliefs that systemic therapy is necessary, weaker concerns about therapy and medicine, greater coherence, and less symptoms of depression.

Patients using self-administered systemic therapy had strong habit strength. Being on a conventional systemic therapy, having strong medication concerns, longer treatment duration, and younger age were factors associated with overall nonadherence. Being on a conventional therapy and strong medication concerns were also significant for intentional nonadherence. Being on a conventional systemic therapy, stronger perceptions of psoriasis being a chronic condition, younger age, and longer treatment duration were factors associated with unintentional nonadherence.

Group 1 membership (strongest medication concerns) was associated with intentional nonadherence, and weaker medication-taking routine or habit strength was associated with unintentional nonadherence.

Dual conceptualization (self-report with psychometric principles) of medication nonadherence has stronger validity and reliability than other forms that confound these 2 variables. Extent of adherence was highly correlated with self-efficacy, where lower adherence levels were associated with lower self-efficacy.

In all, 3 items assessing the extent of nonadherence produced reliable scores. Correlations and comparison measures showed convergent and divergent validity. Predictive validity was evidenced by correlations between extent and BP. Means of the reasons items were well below the scale midpoint, and several distributions were positively skewed and kurtosis. The Morisky scale did not measure a single underlying construct in this sample. The Morisky scale was not correlated with BP.

Other Adherence-Related Outcomes

In addition to habit strength, other factors significantly associated with increased medication adherence included perceived negative consequences of taking the medication [10,11,22,43], perceived behavioral control [10], and older age [10,43]. Longer treatment duration was found to be significantly associated with adherence in 2 different studies. One study [10] concluded that longer treatment duration led to higher adherence because a longer period led to the development of habit. In contrast, another study [43] concluded that longer treatment duration led to higher overall and unintentional nonadherence. Strong concerns were also associated with intentional nonadherence [43]. Stronger perceptions of having a chronic condition and younger age were also associated with unintentional nonadherence [43]. Disease severity also affected adherence behavior. For those taking asthma medications, asthma severity was positively correlated with medication adherence.

http://www.jmir.org/2020/4/e17883/  J Med Internet Res 2020 | vol. 22 | iss. 4 | e17883 | p. 10

---

aASE: attitude, social influence, and self-efficacy model.
bCSM: common sense model.
cT2D: type 2 diabetes.
dNAID: noninsulin antidiabetic drugs.
eFEV: forced expiratory volume.
fOCP: oral contraceptive pill.
gCS-SRM: common sense model of self-regulation.
hMEMS: medication event monitoring system.
iBP: blood pressure.
adherence [22]. Having a fixed time of the day for taking medications was associated with better habit strength and better adherence, but there was no association between habit strength and the time of the day medications were taken [41]. Having a fixed place to store the medication was associated with higher habit strength but not higher medication adherence [41].

In the included studies, factors found to not have a relationship with medication adherence were modeling [22], treatment-related beliefs [9,40], and pill burden [40]. The association of treatment-related beliefs was not stronger for intentional nonadherence than for unintentional nonadherence [9]. One study [40] found that common sense model–related coherence did not have a significant relationship with medication adherence; yet, another study [9] found that CS-SRM coherence was more strongly associated with intentional nonadherence than unintentional nonadherence. Demographics associated with adherence included sex [10,22], education level [10], and income [10]. Although social norms did moderate the relationship between habit strength and medication adherence, it did not have a significant relationship with medication adherence by itself [22]. One study [20] found that there was an interaction between habit strength and mental health symptoms; however, depressed mood, anxiety, and mental health by themselves were not associated with adherence [10]. Patient experiences did not predict overall nonadherence but did predict intentional nonadherence [9].

**Discussion**

**Principal Findings**

Our systematic review contributes to the literature on habit strength and medication adherence across chronic medication conditions. We found that habit strength was strongly correlated with medication adherence, with stronger habit being associated with higher medication adherence rates, regardless of the theoretical model and/or guiding framework. As the behavior becomes more automatic, there is less chance for an individual to forget to take their medicine. We also found that the effect of habit strength on adherence was also related to the individual’s self-efficacy, social norms, and mental health symptoms. This has been explained in earlier studies investigating the dual-process theories, where an individual’s behavior is a result of both deliberative/reflective processes and implicit/impulsive processes [47]. When conscious processes are strong, they might be able to overpower the automaticity of habits. It is also important to note that many of the social influence subscales, as well as habit, were highly intercorrelated in relation to risk perception, pros/cons of taking medication, social support, and self-efficacy [22].

In 1 study [40], it was determined that associations among adherence measures were weak to moderate. This indicates that multiple measures are necessary to accurately assess adherence, as was done in some of the included studies. In addition, self-report questionnaires run the risk of social desirability bias, so monitoring with electronic pill bottles or looking into prescription pharmacy refill records are other important and informative ways of measuring medication adherence.

Our findings in this review suggest that interventions to increase medication adherence could be more effective if they focused on developing a stronger habit among individuals. One way to build a stronger habit is by reminding the patient when it is time to take their medication [18], such as with pill bottle caps that light up when it is time to take the medication. Another approach to strengthen a patient’s habit of taking medication is to leverage technology-based interventions and remind the patient to take their medication by sending a text message or alert on the patient’s phone when it is time to take their dose. Interestingly, a recent review reported that a number of grants, funded by the US National Institutes of Health (2014–2018), were focused on developing and testing mHealth smartphone apps that were specifically designed to facilitate medication adherence behavior by reminding patients to take their scheduled medications, which could lead to the development of a habit [48]. Furthermore, a possible habit-based intervention to increase medication adherence is to incorporate the medication routine into existing lifestyle habits such as physical activity, mealtimes, or morning routines to develop a stronger habit, which should be explored further in future research. However, in this review, we focused our research question on the relationship between habit strength and adherence rates, solely in the context of medication-taking behavior. It is also important to note that most of the included studies in our review were of low quality, and the majority were observational studies, yet they are informative for the most recent evidence on habit strength and medication adherence.

**Strengths**

Our review has some strengths. In all, two authors independently completed the search process at each stage of the systematic review process, following established methodology guidelines (PRISMA). Some of the included studies used multiple forms of measure for medication adherence, making adherence assessment more accurate. Despite having no eligibility restrictions on the year of publication, all the included studies were published between 2011 and 2019, indicating an increasing interest in the topic of habit strength and medication adherence.

**Limitations**

It is important to note some of the limitations of this systematic review. Given that all the search results came from 1 database (ie, PubMed) during the literature search, it is possible that some relevant studies could have been missed during the process. However, most of the studies in other databases, such as PsyCINFO, are also indexed in PubMed, and the chances of missing relevant studies are relatively less. Furthermore, many of the included studies used self-report questionnaires, an approach that has the inherent limitation of social desirability bias. In addition, most of the included studies were observational and cannot evaluate the direction or the cause-and-effect relationship between habit strength and medication adherence. Moreover, it is important to note that the range of countries represented in the included studies was limited and included only developed countries. This is important because lifestyle factors, prescribing practices, and social/cultural norms could be different in different countries, affecting both the development of habit strength and medication adherence behavior. Therefore, the inclusion of studies from only...
developed countries limits the generalizability of this systematic review. Moreover, examining the relationship between habit strength and medication adherence should extend beyond developed countries where all the included studies were conducted. Developing countries have different clinical and research settings, and gaining insight from studies conducted there would be essential for future wide dissemination and implementation efforts of adherence-promoting behavioral interventions. Finally, this systematic review looked primarily at chronic health conditions, and further research should investigate the connection between habit strength and adherence behavior in nonchronic conditions. In addition, future research should also assess the longitudinal relationship between habit strength and medication adherence to better understand their cause-effect association, given that most of the included studies were cross-sectional.

Conclusions
In conclusion, stronger habit has been associated with higher medication adherence rates. This is consistent with published literature indicating that forgetfulness is the leading cause of unintentional medication nonadherence. All studies in the literature examined habit strength in the context of nonadherence. Future rigorous longitudinal studies are needed to examine the direction of the relationship between habit strength and medication adherence behavior.

Acknowledgments
We wish to acknowledge MMAS Research LLC for the use of ©Morisky Widget MMAS-8 software. Morisky Widget MMAS-8 software is protected by U.S. copyright and trademark laws. Permission for use of Morisky Widget MMAS-8 software copyright registration number TX 8-816-517 is required and was obtained for this research. A license agreement is available from MMAS Research LLC, 1501 Spring Hill Red, Petaluma CA, 94952 USA; strubow@morisky.org. We would like to express our gratitude to Steve Trubow for the generous training and the timely license provision.

This project was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (K23HL150232, principal investigator: Badawy). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflicts of Interest
None declared.

Multimedia Appendix 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist.
[DOC File, 63 KB-Multimedia Appendix 1]

References
1. Vrijens B, de Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. May 2012;73(5):691-705. [FREE Full text] [doi: 10.1111/j.1365-2125.2012.04167.x] [Medline: 22486599]
2. Vrijens B, Antoniou S, Burnier M, de la Sierra A, Volpe M. Current situation of medication adherence in hypertension. Front Pharmacol. 2017;8:100. [FREE Full text] [doi: 10.3389/fphar.2017.00100] [Medline: 28298894]
3. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmaco Toxicol. 2012;52:275-301. [doi: 10.1146/annurev-pharmtox-011711-113247] [Medline: 21942628]
4. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. Apr 16, 2008;(2):CD000011. [doi: 10.1002/14651858.CD000011.pub3] [Medline: 18425859]
5. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. Aug 4, 2005;353(5):487-497. [doi: 10.1056/NEJMr050100] [Medline: 16079372]
6. Badawy SM, Thompson AA, Liem RI. Beliefs about hydroxyurea in youth with sickle cell disease. Hematol Oncol Stem Cell Ther. Sep 2018;11(3):142-148. [FREE Full text] [doi: 10.1016/j.hemonc.2018.01.001] [Medline: 29397333]
7. Gupta OT, Wiebe DJ, Pyatak EA, Beck AM. Improving medication adherence in the pediatric population using integrated care of companion animals. Patient Educ Couns. Oct 2018;101(10):1876-1878. [doi: 10.1016/j.pec.2018.05.015] [Medline: 29807672]
8. Badawy SM, Thompson AA, Penedo FJ, Lai J, Rychlik K, Liem RI. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease. Eur J Haematol. Jun 2017;98(6):608-614. [doi: 10.1111/ejh.12878] [Medline: 28306171]
9. Phillips LA, Leventhal H, Leventhal EA. Assessing theoretical predictors of long-term medication adherence: patients’ treatment-related beliefs, experiential feedback and habit development. Psychol Health. 2013;28(10):1135-1151. [doi: 10.1080/08870446.2013.793798] [Medline: 23627524]
10. Guénette L, Breton M, Guillaumie L, Lauzier S, Grégoire JP, Moisan J. Psychosocial factors associated with adherence to non-insulin antidiabetes treatments. J Diabetes Complications. Mar 2016;30(2):335-342. [doi: 10.1016/j.diabcomp.2015.10.016] [Medline: 26615905]

11. Hoo ZH, Gardner B, Arden MA, Waterhouse S, Walters SJ, Campbell MJ, et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax. Feb 2019;74(2):197-199. [doi: 10.1136/thoraxjnl-2017-211453] [Medline: 29886416]

12. Hoo ZH, Wildman MJ, Campbell MJ, Walters SJ, Gardner B. A pragmatic behavior-based habit index for adherence to nebulized treatments among adults with cystic fibrosis. Patient Prefer Adhere. 2019;13:283-294. [FREE Full text] [doi: 10.2147/PPA.S186417] [Medline: 30863018]

13. Badawy SM, Thompson AA, Lai J, Penedo FJ, Rychlik K, Liem RI. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer. Jun 2017;64(6):e26369. [doi: 10.1002/pbc.26369] [Medline: 27896936]

14. Badawy SM, Thompson AA, Lai J, Penedo FJ, Rychlik K, Liem RI. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults. Health Qual Life Outcomes. Jul 5, 2017;15(1):136. [FREE Full text] [doi: 10.1186/s12955-017-0713-x] [Medline: 28679417]

15. Badawy SM, Barrera L, Cai S, Thompson AA. Association between participants' characteristics, patient-reported outcomes, and clinical outcomes in youth with sickle cell disease. Biomed Res Int. 2018;2018:8296139. [FREE Full text] [doi: 10.1155/2018/8296139] [Medline: 30105252]

16. Badawy SM, Thompson AA, Holl JL, Penedo FJ, Liem RI. Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease. Pediatr Hematol Oncol. 2018;35(5-6):297-308. [doi: 10.1080/08880018.2018.1505988] [Medline: 30636474]

17. Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy. 2014;7:35-44. [FREE Full text] [doi: 10.2147/RMHP.S19801] [Medline: 24591853]

18. Gardner B. A review and analysis of the use of 'habit' in understanding, predicting and influencing health-related behaviour. Health Psychol Rev. 2015;9(3):277-295. [FREE Full text] [doi: 10.1080/17437199.2013.876238] [Medline: 25207647]

19. Wood W, Rünger D. Psychology of habit. Annu Rev Psychol. 2016;67:289-314. [doi: 10.1146/annurev-psych-122414-033417] [Medline: 26361052]

20. Burns RJ, Deschénes SS, Knäuper B, Schmitz N. Habit strength as a moderator of the association between symptoms of poor mental health and unintentional non-adherence to oral hypoglycemic medication in adults with type 2 diabetes. J Health Psychol. Mar 2019;24(3):321-326. [doi: 10.1177/1359105316674269] [Medline: 28810360]

21. Sawyer SM, Fardy HJ. Bridging the gap between doctors' and patients' expectations of asthma management. J Asthma. Apr 2003;40(2):131-138. [doi: 10.1081/jas-120017983] [Medline: 12765314]

22. Bolman C, Arwert TG, van der Vleuten CP, Breukers CM, van der Heijden GJ, Beersma MG, et al. A non-adherence checklist of asthmatic patients. J Asthma. Apr 2011;48(3):261-267. [doi: 10.3109/02770903.2010.512638] [Medline: 20651874]

23. Badawy SM, Thompson AA, Liem RI. Technology access and smartphone app preferences for medication adherence in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer. May 2016;63(5):848-852. [doi: 10.1002/pbc.26369] [Medline: 28644685]

24. Andersen M, Jiang J. Pew Research Center. 2018. URL: https://www.pewresearch.org/internet/2018/05/31/teens-social-media-technology-2018/ [accessed 2020-01-17]

25. Pew Research Center. 2019. URL: https://www.pewresearch.org/internet/fact-sheet/mobile/ [accessed 2020-01-17]

26. Badawy SM, Barrera L, Sinno MG, Kaviani S, O'Dwyer LC, Kuhns LM. Text messaging and mobile phone apps as interventions to improve adherence in adolescents with chronic health conditions: a systematic review. JMIR Mhealth Uhealth. May 15, 2017;5(5):e66. [FREE Full text] [doi: 10.2196/mhealth.7798] [Medline: 28506955]

27. Badawy SM, Cronin RM, Hankins J, Crosby L, DeBaun M, Thompson AA, et al. Patient-centered ehealth interventions for children, adolescents, and adults with sickle cell disease: systematic review. J Med Internet Res. Jul 19, 2018;20(7):e10940. [FREE Full text] [doi: 10.2196/mhealth.7798] [Medline: 30026178]

28. Badawy SM, Kuhns LM. Texting and mobile phone app interventions for improving adherence to preventive behavior in adolescents: a systematic review. JMIR Mhealth Uhealth. Apr 19, 2017;5(4):e50. [FREE Full text] [doi: 10.2196/mhealth.6837] [Medline: 28428157]

29. Ramsey WA, Heidelberg RE, Gilbert AM, Heneghan MB, Badawy SM, Alberts NM. eHealth and mhealth interventions in pediatric cancer: a systematic review of interventions across the cancer continuum. Psychooncology. Jan 2020;29(1):17-37. [doi: 10.1002/pbc.25905] [Medline: 31692183]

30. Payne HE, Lister C, West JH, Bernhardt JM. Behavioral functionality of mobile apps in health interventions: a systematic review of the literature. JMIR Mhealth Uhealth. Feb 26, 2015;3(1):e20. [FREE Full text] [doi: 10.2196/mhealth.3335] [Medline: 25803705]

31. Thakkar J, Kurup R, Laba T, Santo K, Thiagalingam A, Rodgers A, et al. Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis. JAMA Intern Med. Mar 2016;176(3):340-349. [doi: 10.1001/jamainternmed.2015.7667] [Medline: 26831740]
32. Whitehead L, Seaton P. The effectiveness of self-management mobile phone and tablet apps in long-term condition management: a systematic review. J Med Internet Res. May 16, 2016;18(5):e97. [FREE Full text] [doi: 10.2196/jmir.4883] [Medline: 27185295]

33. Zhao J, Freeman B, Li M. Can mobile phone apps influence people's health behavior change? An evidence review. J Med Internet Res. Oct 31, 2016;18(11):e287. [FREE Full text] [doi: 10.2196/jmir.5692] [Medline: 27806926]

34. Britto MT, Rohan JM, Dodds CM, Byczkowski TL. A randomized trial of user-controlled text messaging to improve asthma outcomes; a pilot study. Clin Pediatr (Phila). Dec 2017;56(14):1336-1344. [doi: 10.1177/0009922816684857] [Medline: 28056541]

35. Badawy SM, Thompson AA, Kuhns LM. Medication adherence and technology-based interventions for adolescents with chronic health conditions: a few key considerations. JMIR Mhealth Uhealth. Dec 22, 2017;5(12):e202. [FREE Full text] [doi: 10.2196/mhealth.8310] [Medline: 29273574]

36. Liberati A, Altman DG, Tetzlaff J,Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J. Jul 21, 2009;339:b2700. [FREE Full text] [doi: 10.1136/bmj.b2700] [Medline: 19622552]

37. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. Apr 2011;64(4):401-406. [doi: 10.1016/j.jclinepi.2010.07.015] [Medline: 21208779]

38. Murphy J, Eustace N, Sarma KM, Molloy GJ. Habit strength and adherence to oral contraceptives: the role of time- and place-based cues. Int J Behav Med. Aug 2018;25(4):431-437. [doi: 10.1007/s12529-018-9729-9] [Medline: 29856008]

39. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. Apr 2011;64(4):401-406. [doi: 10.1016/j.jclinepi.2010.07.015] [Medline: 21208779]

40. Murphy J, Eustace N, Sarma KM, Molloy GJ. Habit strength and adherence to oral contraceptives: the role of time- and place-based cues. Int J Behav Med. Aug 2018;25(4):431-437. [doi: 10.1007/s12529-018-9729-9] [Medline: 29856008]

41. Murphy J, Eustace N, Sarma KM, Molloy GJ. Habit strength and adherence to oral contraceptives: the role of time- and place-based cues. Int J Behav Med. Aug 2018;25(4):431-437. [doi: 10.1007/s12529-018-9729-9] [Medline: 29856008]

42. Murphy J, Eustace N, Sarma KM, Molloy GJ. Habit strength and adherence to oral contraceptives: the role of time- and place-based cues. Int J Behav Med. Aug 2018;25(4):431-437. [doi: 10.1007/s12529-018-9729-9] [Medline: 29856008]

43. Badawy SM, Kuhns LM. Medication adherence and technology-based interventions for adolescents with chronic health conditions: a systematic review. JMIR Mhealth Uhealth. Oct 25, 2016;4(4):e121. [FREE Full text] [doi: 10.2196/mhealth.6425] [Medline: 27780795]

44. Liberati A, Altman DG, Tetzlaff J, McManus IC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J. Jul 21, 2009;339:b2700. [FREE Full text] [doi: 10.1136/bmj.b2700] [Medline: 19622552]

45. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. Apr 2011;64(4):401-406. [doi: 10.1016/j.jclinepi.2010.07.015] [Medline: 21208779]

46. Durand H, Hayes P, Harhen B, Conneely A, Finn DP, Casey M, et al. Medication adherence for resistant hypertension: a process model. Psychol Bull. Nov 2017;143(11):1117-1154. [doi: 10.1037/bul0000118] [Medline: 28805401]

47. Badawy SM, Thompson AA, Kuhns LM. Medication adherence and technology-based interventions for adolescents with chronic health conditions: a systematic review. JMIR Mhealth Uhealth. Dec 22, 2017;5(12):e202. [FREE Full text] [doi: 10.2196/mhealth.8310] [Medline: 29273574]

48. Liberati A, Altman DG, Tetzlaff J, McManus IC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J. Jul 21, 2009;339:b2700. [FREE Full text] [doi: 10.1136/bmj.b2700] [Medline: 19622552]

Abbreviations

ASE: attitude, social influence, and self-efficacy model
COM-B: capability, opportunity, motivation, and behavior model
CS-SRM: common sense model of self-regulation
mHealth: mobile health
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
TPB: theory of planned behavior

http://www.jmir.org/2020/4/e17883/
